News
Entertainment
Science & Technology
Life
Culture & Art
Hobbies
News
Entertainment
Science & Technology
Culture & Art
Hobbies
Discover Latest #FED News, Articles and Videos with Contenting
July 9, 2019 The Week: On Monday, the Federal Reserve announced that it was cutting interest rates for the first time since the financial crisis. The cut was seen as a response to the economic slowdown that has been seen in the U.S. and around the world. The Fed also indicated that it may cut rates further if needed. The news sent stocks soaring, and the U.S. dollar fell sharply against other major currencies. On Tuesday, the Federal Reserve released its quarterly economic report, which showed that the U.S. economy is slowing. The report showed that consumer spending, business investment, and exports were all weaker than expected. The report also showed that inflation has been running below the Fed's 2% target. On Wednesday, the Federal Reserve released the minutes from its June meeting, which showed that officials were split on the decision to cut interest rates. Some officials argued for a larger cut, while others felt that a smaller cut was sufficient. The minutes also showed that the Fed was divided on what to do next, with some arguing for further rate cuts, while others were hesitant to do so. On Thursday, the Labor Department released its monthly jobs report, which showed that the U.S.
European Shares Seen Lower; Central Bank Decisions And Trump's Tariff Plans In Focus - ForexTV
European stocks are anticipated to open predominantly lower on Thursday as investors seek further clarity regarding U.S. President Donald Trump's policy agenda.Asian markets displayed mixed trends, with upticks observed in the Chinese and Hong Kong markets. This followed the announcement of medium- and long-term investment plans by several Chinese government departments aimed at bolstering the country's struggling stock market.China has unveiled a strategic initiative to channel hundreds of billions of yuan annually from state-owned insurance companies into the stock market. This move is intended to enhance investor confidence and revitalize the market.The US dollar strengthened in anticipation of a series of central bank decisions expected in the coming week. Concurrently, gold edged down from a near three-month high, whereas oil prices decreased following industry reports indicating the first increase in U.S. crude stockpiles since mid-November.The yen remained relatively stable amid expectations that the Bank of Japan will raise interest rates at the conclusion of its two-day policy meeting on Friday.In terms of economic data releases, attention later in the day may turn to Eurozone consumer confidence survey results, alongside U.S. data on initial jobless claims and the Kansas City Fed manufacturing index.The U.S. stock market experienced gains overnight, propelling Wall Street toward record highs. This surge was supported by strong quarterly results from Netflix, optimism surrounding potential Federal Reserve rate cuts, and President Trump's new initiative focusing on artificial intelligence.The Dow Jones Industrial Average increased by 0.3%, the S&P 500 rose by 0.6%, and the technology-centric Nasdaq Composite advanced by 1.3%.On Wednesday, European stocks broadly rose, with sentiment bolstered by expectations of rate cuts from both the Federal Reserve and the European Central Bank, which countered concerns over Trump's tariff threats.The pan-European STOXX 600 index increased by 0.4%, reaching a nearly four-month high. Germany's DAX index climbed 1% to close at an all-time high, buoyed by Adidas’s strong holiday quarter performance. France's CAC 40 index jumped 0.9%, while the U.K.'s FTSE 100 ended slightly lower.The material has been provided by InstaForex Company - www.instaforex.com
Cancer Research UK, Cytovation and the Norwegian Cancer Society collaborate to advance treatment for rare cancer - ForexTV
Collaboration to take Cytovation’s synthetic peptide, CY-101, into a Phase 2 trial for patients with adrenocortical carcinomaCancer Research UK’s Centre for Drug Development to run the trial at sites in UK, and others across EuropeThe Norwegian Cancer Society to provide co-funding to support the trial LONDON, UK, and BERGEN and OSLO, Norway, 23 January 2025 – Cancer Research UK, Cytovation and the Norwegian Cancer Society have signed an agreement to bring Cytovation’s lead asset, CY-101, into a multi-national Phase 2 clinical trial for patients with adrenocortical carcinoma (ACC). This rare and aggressive cancer, which affects the adrenal glands, has limited treatment options and an urgent need for new therapies. CY-101, developed by Cytovation, is a synthetic peptide with a dual function. It selectively targets and destroys cancer cells, triggering a systemic immune response, while simultaneously inhibiting the Wnt/β-catenin signalling pathway, a key driver of immunotherapy resistance in cancers such as ACC. CY-101’s development builds on compelling data from Cytovation’s Phase 1 CICILIA trial, which demonstrated encouraging outcomes in patients with solid tumours. Notably, two ACC patients had clear clinical benefit, with one achieving 18 months of progression-free survival and continuing treatment on a named-patient basis. These results highlight CY-101’s potential to address the specific mechanisms of ACC. A collaborative approach Under the agreement, Cancer Research UK’s Centre for Drug Development (CDD) will sponsor, design and deliver the Phase 2 trial and Cytovation will be responsible for providing CY-101 for the clinical trial. Cancer Research Horizons, Cancer Research UK’s innovation arm, will manage the commercial relationship between the three parties. The Norwegian Cancer Society’s support provides access to the additional resources, patients and sites required for trials in rare diseases. Due to the rarity of ACC, the clinical trial will run across multiple sites in the UK and Europe, to ensure robust patient recruitment. Lars Erwig, Director of the Centre for Drug Development, Cancer Research UK, said: “This collaboration represents a critical step toward addressing the needs of ACC patients who currently have very few treatment options. Cytovation has made impressive progress with CY-101 so far and we are excited to build on our existing partnership with the Norwegian Cancer Society to take its development further.” Lars Prestegarden, CEO, Cytovation, said: “We are very excited about this partnership, proud to follow in the footsteps of groundbreaking agents that Cancer Research UK has contributed to developing, and honoured by the Norwegian Cancer Society’s support. We believe CY-101 has the potential to be transformational for the treatment of ACC and other cancer types and are eager to bring this innovation to patients.” Ingrid Stenstadvold Ross, CEO of the Norwegian Cancer Society, said: “The partnership with Cancer Research UK’s Centre for Drug Development marks a milestone for the Norwegian Cancer Society, enabling us to advance the development of groundbreaking cancer treatments. We are thrilled that our first joint project is a Norwegian innovation, focused on patients with a rare cancer and a substantial unmet need. Together with Cancer Research UK’s Centre for Drug Development and Cytovation, we are bringing new hope to patients while highlighting Norwegian research on the international stage.” ENDS About Cancer Research UK’s Centre for Drug Development Cancer Research UK has an impressive record of developing novel treatments for cancer. The Cancer Research UK Centre for Drug Development has been pioneering the development of new cancer treatments for 30 years, taking over 160 potential new anti-cancer agents into clinical trials in patients. Six of these new agents have made it to market, including temozolomide for brain cancer, abiraterone for prostate cancer and rucaparib for ovarian cancer. Two other drugs are in late development Phase 3 trials. Thirteen agents remain in active development with the potential to reach the market. It currently has a portfolio of 16 projects in preclinical development, Phase 1 or early Phase 2 clinical trials. www.cruk.org.uk/cdd About Cytovation Cytovation ASA is a clinical stage biotech company focused on the development of CY-101, a first-in-class bifunctional immunotherapy. CY-101 has a unique dual mechanism of action, specifically eliminating cancer cells by targeting the cell membrane and releasing neo-antigens, and by inhibiting the Wnt/β-catenin oncogenic pathway to restrict tumour growth and reverse immune exclusion associated with β-catenin expression. Dysregulation of this pathway has been associated with several different cancer types including colon, liver, uterine, lung and ovarian cancer, among others. This dual mode of action induces a systemic, tumour-specific immune response. For more information, please visit www.cytovation.com. About the Norwegian Cancer Society The Norwegian Cancer Society (NCS) is one of the largest organisations in Norway. It represents the voices of those affected by cancer. We have 128,000 members, 27,000 volunteers and 190 employees. All are dedicated to promoting cancer cause. NCS works continuously to improve society’s attitude to the prevention and treatment of cancer. We fight cancer locally, nationally and globally. Through research and preventive measures, information, support, advice and lobbying. The Norwegian Cancer Society’s purpose is to work to prevent and fight cancer. And to improve quality of life for patients and their families. Our vision is a life without cancer. For further information about the work of NCS, please visit www.kreftforeningen.no. Contacts Cancer Research UK Tim Bodicoat Content Manager Cancer Research UK tim.bodicoat@cancer.org.uk Cytovation ASA Federico GregoCOO/CFOCytovation ASAcontact@cytovation.com Frazer Hall/Mark Swallow MEDiSTRAVA cytovation@medistrava.com Norwegian Cancer Society Ola Henmo Norwegian Cancer Society ola.henmo@kreftforeningen.no
Bain matches CC Capital’s offer for Australia’s Insignia Financial at $1.92 billion By Reuters - Forex Trader Hub
By Roushni Nair (Reuters) -Insignia Financial's shares hit a three-year high on Thursday, driven by a revised takeover offer of A$3.07 billion ($1.92 billion) from U.S.-based Bain Capital, matching the bid of rival CC Capital Partners (WA:) and fuelling a heated bidding war. Insignia Financial had previously rebuffed an approach from private equity firm Bain